Laughing Water Capital Reports Quarterly Gains and Highlights Liquidia Stock
Laughing Water Capital released its Q4 2025 investor letter, reporting a 6.8% return for the quarter and highlighting Liquidia Corporation's performance and drug approval.
Topic
Latest reporting and analysis tagged with biopharmaceuticals.
Laughing Water Capital released its Q4 2025 investor letter, reporting a 6.8% return for the quarter and highlighting Liquidia Corporation's performance and drug approval.
Ascendis Pharma announced Q4 product revenue of about €240M and full-year revenue of about €683M at the J.P. Morgan Healthcare Conference, highlighting profitability, Yorvipath expansion, and upcoming regulatory decisions.